TITLE

New taxane treats advanced prostate cancer

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/1/2010, Vol. 67 Issue 15, p1220
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the cabazitaxel drug from Sanofi-Aventis for the treatment of androgen-independent prostate cancer in men. It states that the drug can be provided to patients who experienced worsened case of prostate cancer due to docetaxel therapy. It says recommendations for the drug include infusion over one hour within three weeks, oral prednisone of 10 mg, and intravenous treatment for 30 minutes. It adds that the drug has additional ethanol solution and sodium chloride injection.
ACCESSION #
52449240

 

Related Articles

  • Sanofi-Aventis: Jevtana positioned to help offset Taxotere decline.  // PharmaWatch: Monthly Review;Apr2010, Vol. 9 Issue 4, p7 

    The article reports on the findings of a pivotal study on Sanofi-Aventis SA's Jevtana drug which depicted its capacity to improve the median overall survival of patients with prostate cancer. It states that the company has planned to promote the drug as a replacement for the Taxotere, which...

  • Panel Gives Cell Genesys OK to Continue Prostate Trial. Young, Donna // BioWorld Today;1/15/2008, Vol. 19 Issue 10, p3 

    The article announces the approval to continue Cell Genesys Incorporated's Phase III clinical trial of its prostate cancer immunotherapeutic GVAX. The study is comparing GVAX with Sanofi-Aventis Group's chemotherapy agent Taxotere plus prednisone in patients with hormone-refractory prostate...

  • Taxotere.  // Royal Society of Medicine: Medicines;2002, p523 

    The article presents information on the Taxotere drug which is a proprietary, prescription-only preparation of the anticancer drug docetaxel. This drug can be used to treat breast cancer, and is available in a form for intravenous infusion.

  • Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Rosing, H.; Lustig, V.; Van Warmerdam, L. J. C.; Huizing, M. T.; Bokkel Huinink, W. W. Ten; Schellens, J. H. M.; Rodenhuis, S.; Bult, A.; Beijnen, J. H. // Cancer Chemotherapy & Pharmacology;Mar2000, Vol. 45 Issue 3, p213 

    Docetaxel, a taxane antitumor agent, was administered to 24 patients by a 1-h intravenous infusion at a dose level of 100 mg/m2 with pharmacokinetic monitoring. The plasma concentration-versus-time data were fitted with a three-compartment model. The mean area under the curve (AUC) for docetaxel...

  • Sanofi-Aventis: Jevtana positioned to help offset Taxotere decline.  // PharmaWatch: Cancer;Apr2010, Vol. 9 Issue 4, p5 

    The article reports on the effectiveness of Sanofi-Aventis SA's intravenous drug Jevtana. It states that the combination of prednisone and Jevtana semi-synthetic taxane will help reduce the risk of death of second-line castration-resistant prostrate cancer (CRPC) patients by 30%. It says that...

  • European Oncology Conference.  // BioWorld Today;9/24/2009, Vol. 20 Issue 184, p3 

    The article reports that Hybrigenics SA discussed the interim results of its Phase II trial of inecalcitol and Tacotere from Sanofi-Aventis Group against hormone-refractory prostate cancer at the European Oncology Conference held in Berlin, Germany. According to the study, 33 of the 38 evaluable...

  • Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Buonerba, Carlo; Federico, Piera; D'Aniello, Carmine; Rescigno, Pasquale; Cavaliere, Carla; Puglia, Livio; Ferro, Matteo; Altieri, Vincenzo; PerdonĂ , Sisto; Placido, Sabino; Di Lorenzo, Giuseppe // Cancer Chemotherapy & Pharmacology;Jun2011, Vol. 67 Issue 6, p1463 

    No abstract available.

  • Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Buonerba, Carlo; Federico, Piera; D'Aniello, Carmine; Rescigno, Pasquale; Cavaliere, Carla; Puglia, Livio; Ferro, Matteo; Altieri, Vincenzo; PerdonĂ , Sisto; De Placido, Sabino; Lorenzo, Giuseppe // Cancer Chemotherapy & Pharmacology;Jun2011, Vol. 67 Issue 6, p1455 

    Background: Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Methods: Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of...

  • Abiraterone.  // AHFS Consumer Medication Information;Feb2017, p1 

    Abiraterone is used in combination with another medication (prednisone) to treat prostate cancer that has spread to other parts of the body in men who have not been helped by other treatments including docetaxel (Docefrez, Taxotere). Abiraterone is in a class of medications called androgen...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics